LYTIR

Company · BBIO

BridgeBio Pharma, Inc.

Nasdaq's symbol directory lists BBIO on Nasdaq as “BridgeBio Pharma, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 12 occasions ($28.4M); 5 filings by holders of 5% or more; 8 congressional trade disclosures; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $28.4M in total.Jun: Insider sales $9.1MJul: Insider sales $14.8MAug: Insider sales $3.7MSep: Insider sales $691KOct: Insider sales $146KDecJanFebMarAprMayJunJulAugSepOctNov$14.8M
Insider purchases above the line: $0Insider sales below: $28.4M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Jennifer E. Cook sold on 4 days all under a 10b5-1 plan latest Jul 9, 2026 sold $21.9M
  2. Kumar Neil, Chief Executive Officer sold on 3 days all under a 10b5-1 plan latest Sep 17, 2026 sold $4.4M
  3. Ellis Andrea sold on 1 day all under a 10b5-1 plan latest Jul 9, 2026 sold $1.4M
  4. Valantine Hannah sold on 2 days all under a 10b5-1 plan latest Jun 23, 2026 sold $342K
  5. Apuli Maricel, Chief Accounting Officer sold on 2 days all under a 10b5-1 plan latest Oct 30, 2026 sold $306K
Every trade (12)
  1. SELLApuli Maricel, Chief Accounting Officer sold Oct 30, 2026 2,000 shares 10b5-1 plan (scheduled) filing $146K
  2. SELLKumar Neil, Chief Executive Officer sold Sep 17, 2026 10,000 shares 2 legs combined 10b5-1 plan (scheduled) filing $691K
  3. SELLKumar Neil, Chief Executive Officer sold Aug 19, 2026 10,000 shares 3 legs combined 10b5-1 plan (scheduled) filing $840K
  4. SELLKumar Neil, Chief Executive Officer sold Aug 18, 2026 34,980 shares 4 legs combined 10b5-1 plan (scheduled) filing $2.9M
  5. SELLApuli Maricel, Chief Accounting Officer sold Jul 30, 2026 2,000 shares 10b5-1 plan (scheduled) filing $160K
  6. SELLJennifer E. Cook sold Jul 9, 2026 148,589 shares 2 legs combined 10b5-1 plan (scheduled) filing $13.2M
  7. SELLEllis Andrea sold Jul 9, 2026 17,167 shares 10b5-1 plan (scheduled) filing $1.4M
  8. SELLJennifer E. Cook sold Jun 24, 2026 37,167 shares 10b5-1 plan (scheduled) filing $2.6M
  9. SELLJennifer E. Cook sold Jun 23, 2026 2,196 shares 10b5-1 plan (scheduled) filing $151K
  10. SELLValantine Hannah sold Jun 23, 2026 2,196 shares 10b5-1 plan (scheduled) filing $151K
  11. SELLValantine Hannah sold Jun 22, 2026 2,808 shares 10b5-1 plan (scheduled) filing $191K
  12. SELLJennifer E. Cook sold Jun 15, 2026 90,240 shares 2 legs combined 10b5-1 plan (scheduled) filing $6.0M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Farallon Capital Management, L.L.C. filed Nov 12, 2026 Schedule 13G/A passive filing 7.3%
  2. BlackRock, Inc. filed Oct 27, 2026 Schedule 13G passive 9,892,226 shares filing 5.1%
  3. KKR Genetic Disorder L.P. filed Aug 17, 2026 Schedule 13D/A may seek influence 8,260,971 shares filing 4.2%
  4. Farallon Capital Management, L.L.C. filed Aug 3, 2026 Schedule 13G/A passive filing 5.5%
  5. VIKING GLOBAL INVESTORS LP filed Jul 10, 2026 Schedule 13D/A may seek influence 9,792,219 shares filing 5%

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Gilbert Cisneros (D-CA31): Purchase Nov 2, 2026 reported Nov 10, 2026 one of 65 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  2. Gilbert Cisneros (D-CA31): Purchase Oct 27, 2026 reported Nov 10, 2026 one of 65 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  3. Gilbert Cisneros (D-CA31): Sale Sep 29, 2026 reported Oct 12, 2026 one of 57 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  4. Gilbert Cisneros (D-CA31): Purchase May 11, 2026 reported Jun 8, 2026 one of 103 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  5. Gilbert Cisneros (D-CA31): Purchase Apr 29, 2026 reported May 8, 2026 one of 94 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  6. Gilbert Cisneros (D-CA31): Purchase Mar 19, 2026 reported Apr 7, 2026 one of 141 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  7. Gilbert Cisneros (D-CA31): Purchase Mar 18, 2026 reported Apr 7, 2026 one of 141 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  8. Gilbert Cisneros (D-CA31): Purchase Mar 3, 2026 reported Apr 7, 2026 one of 141 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000

Executive branch · OGE Form 278-T

Reported by the President

1 confirmed trade on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports

  1. Purchase: BRIDGEBIO PHARMA INC May 18, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (2) $1,001 – $15,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Oct 29, 2026
  2. Other events filing Oct 13, 2026

Lobbying · Senate LDA reports

Lobbying filed

3 quarterly lobbying reports for 2026 naming BridgeBio Pharma, Inc. as the client: 3 filed by the company itself. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.

  1. The company itself Q3 2026 filing $510K
  2. The company itself Q2 2026 filing $500K
  3. The company itself Q1 2026 filing $420K

Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.